Employees: 635
Size Nanjing Vishee Medical Technology (688580.SS) is a China Health Care company (Medical Specialties) with a market value of $499M, the 3707th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥35.21 on 18 Nov 2026.
Performance Over six months the shares fell 43.4%, against -16.1% for the median peer and -20.0% for the China market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue grew 6.9% over the last twelve months (peer median +5.5%); the operating margin is 24.2% (peer median 2.5%).
Valuation It trades at 19.7× forward earnings against a peer median of 22.4× (5th cheapest of 10).
Price implies For today's price to make sense, revenue must grow about 20% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +16 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.4 points above its cost of capital (11.5% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥462M | CN¥458M | CN¥395M | CN¥458M | CN¥319M |
| Revenue growth | — | +16% | -14% | +44% | — |
| Gross profit | CN¥311M | CN¥285M | CN¥245M | CN¥316M | CN¥221M |
| EBITDA | n/a | CN¥161M | CN¥106M | CN¥137M | CN¥85.3M |
| Net income | CN¥160M | CN¥138M | CN¥102M | CN¥136M | CN¥93.8M |
| Free cash flow | CN¥31.6M | CN¥71.2M | CN¥16.5M | CN¥11.3M | CN¥6.56M |
| Capital expenditure | CN¥133M | CN¥118M | CN¥113M | CN¥133M | CN¥95.6M |
| Total debt | CN¥271,321 | CN¥1.05M | CN¥30.0M | CN¥27.1M | CN¥1.19M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688580.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.9% | -3.8% | 3rd lowest of 21 |
| 6-month return | -43.4% | -16.1% | 3rd lowest of 21 |
| Distance from 52-week high | -51.3% | -37.9% | 3rd lowest of 21 |
| Revenue growth (TTM) | +6.9% | +5.5% | 11th highest of 21 |
| Operating margin | 24.2% | 2.5% | 3rd highest of 21 |
| Forward P/E | 19.7× | 22.4× | 5th cheapest of 10 |
| Growth the price implies (Req g, 7 yrs) | 20.1% | 4.5% | 3rd most demanding of 10 |
| Growth delivered (Del g) | +4.2% | -4.3% | 5th highest of 10 |
| Hurdle (Req g minus delivered) | +15.9 pp | -0.5 pp | 3rd most demanding of 10 |
| ROIC minus cost of capital | +0.4 pp | -1.6 pp | 6th highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Nanjing Vishee Medical Technology 688580.SS | China | $499M | -43% | +7% | 24% | 19.7× | 20.1% | +4.2% |
| Zhejiang Orient Gene Biotech 688298.SS | China | $500M | -27% | +18% | -60% | n/a | n/a | n/a |
| medmix MEDX.SW | Switzerland | $494M | +11% | -7% | 6% | 19.4× | 4.5% | +5.0% |
| Assure Tech (Hangzhou) 688075.SS | China | $508M | -27% | -9% | -8% | n/a | 30.8% | -18.6% |
| Anteris Technologies Global AVR | United States | $508M | -40% | +9% | -4,880% | n/a | n/a | n/a |
| Zhejiang Starry Pharmaceutical 603520.SS | China | $491M | -44% | +9% | 3% | 25.8× | n/a | n/a |
| Shofu 7979.T | Japan | $510M | +32% | +9% | 14% | 13.2× | n/a | n/a |
| Guangdong Hybribio Biotech 300639.SZ | China | $511M | -18% | -7% | 4% | 57.3× | 0.4% | -13.2% |
| Wuhan Easy Diagnosis Biomedicine 002932.SZ | China | $485M | -14% | -9% | -51% | n/a | n/a | n/a |
| Hangzhou Alltest Biotech 688606.SS | China | $484M | -20% | 0% | 13% | 6.9× | -6.5% | -4.3% |
| Medprin Regenerative Medical Technologies 301033.SZ | China | $482M | -14% | +23% | 31% | 22.4× | 4.3% | +24.4% |
| Anbio Biotechnology NNNN | United States | $518M | -89% | +10% | 67% | n/a | n/a | n/a |
| MedicalSystem Biotechnology 300439.SZ | China | $518M | -9% | +14% | 2% | n/a | 6.0% | -7.7% |
| Guangdong Biolight Meditech 300246.SZ | China | $478M | -35% | +7% | -8% | n/a | 55.3% | -4.7% |
| CellaVision CEVI.ST | Sweden | $477M | +64% | +2% | 23% | 32.6× | 7.1% | +10.0% |
| AngioDynamics ANGO | United States | $476M | -4% | +8% | -6% | n/a | n/a | n/a |
| WELL LEAD MEDICAL 603309.SS | China | $473M | -22% | +1% | 15% | 11.9× | -5.9% | +7.7% |
| AVITA Medical RCEL | United States | $529M | +290% | +17% | -34% | n/a | n/a | n/a |
| Myriad Genetics MYGN | United States | $530M | +45% | -3% | -13% | n/a | n/a | n/a |
| Jin Medical International ZJYL | United States | $532M | +47% | -14% | 2% | n/a | n/a | n/a |
| Eiken Chemical 4549.T | Japan | $466M | -20% | +4% | 6% | 24.5× | n/a | n/a |